The LNP-mRNA modality is a novel approach that uses lipid nanoparticles to deliver messenger RNA into cells. The mRNA acts as ...

AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has received approval from ...

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, ...

The FDA has approved Enhertu (fam-trastuzumab deruxtecan-nxki) for HR-positive, HER2-low or HER2-ultralow metastatic breast cancer.

January's FDA oncology approvals offer new treatment options for breast cancer, mantle cell lymphoma, and other malignancies.

This study presents a useful finding that targeting amino acid metabolism can overcome Trastuzumab resistance in HER2+ breast cancer. The evidence supporting the claims of the authors is solid and the ...

The dimensions of membrane-tethered anti-CD3 and pMHC molecules were ... or 3T3 APCs were stained with commercial antibodies at the recommended dilutions. The dead cells were gated out by staining ...

Dr. Won Jin Ho presented a talk as part of the Immunology Neighborhood Seminar on “Overcoming the tumor immune ...

Annexin V-PE and 7-AAD staining solutions were then added to ... transferred onto a polyvinylidene difluoride (PVDF) membrane and incubated overnight with primary antibodies from Cell Signaling ...

The fatty membrane surrounding every living cell is a vibrant environment where countless biological processes take place.